Poly (ADP-ribose) polymerase (PARP) inhibitors are increasingly being studied as cancer
drugs, as single agents, or as a part of combination therapies. Imaging of PARP using a …

Poly (ADP-ribose) polymerase (PARP) is involved in repair of DNA breaks and is over-
expressed in a wide variety of tumors, making PARP an attractive biomarker for positron …

Purpose Imaging the PARP expression using 18F probes has been approved in clinical
trials. Nevertheless, hepatobiliary clearance of both 18F probes hindered their application in …

A number of small-molecule poly (ADP-ribose) polymerase (PARP) inhibitors are currently
undergoing advanced clinical trials. Determining the distribution and target inhibitory activity …

Interest in nuclear imaging of poly (ADP-ribose) polymerase-1 (PARP-1) has grown in recent
years due to the ability of PARP-1 to act as a biomarker for glioblastoma and increased …

Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme in the DNA repair process
and the target of several FDA-approved inhibitors. Several of these inhibitors have been …

Imaging of poly (ADP-ribose) polymerase-1 (PARP-1) expression in vivo is a potentially
powerful tool for developing PARP-1 inhibitors for drug discovery and patient care. We have …

Given the clinical potential of poly (ADP-ribose) polymerases (PARP) imaging for the
detection and stratification of various cancers, the development of novel PARP imaging …

Positron emission tomography (PET) is a diagnostic nuclear imaging modality that relies on
automated protocols to prepare agents labeled with a positron-emitting radionuclide (eg …

Purpose To demonstrate that positron emission tomography (PET) with fluorine 18 (18F)
fluorthanatrace (FTT) depicts activated poly (adenosine diphosphate–ribose) polymerase …